Bendik Lund
Overview
Explore the profile of Bendik Lund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taalas T, Oskarsson T, Heyman M, Lund B, Lepik K, Vaitkeviciene G, et al.
Haematologica
. 2025 Feb;
PMID: 39973352
Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL...
2.
Brandt A, Ro T, Finnanger T, Hypher R, Lien E, Lund B, et al.
Front Neurol
. 2024 Jan;
14:1192623.
PMID: 38249741
Background: Pediatric acquired brain injury (pABI) profoundly affects cognitive functions, encompassing IQ and executive functions (EFs). Particularly, young age at insult may lead to persistent and debilitating deficits, affecting daily-life...
3.
Helenius M, Vaitkeviciene G, Abrahamsson J, Jonsson O, Lund B, Harila-Saari A, et al.
Pediatr Blood Cancer
. 2022 Mar;
69(6):e29582.
PMID: 35316565
Background: White blood cell count (WBC) as a measure of extramedullary leukemic cell survival is a well-known prognostic factor in acute lymphoblastic leukemia (ALL), but its biology, including impact of...
4.
Rasouli O, Vegsund H, Eilegard Wallin A, Hjemdal O, Reinfjell T, Moksnes U, et al.
BMJ Support Palliat Care
. 2021 Nov;
13(e3):e1029-e1037.
PMID: 34732472
Objectives: The study aimed to compare the quality of life (QoL) among cancer-bereaved parents with a control group and explore how resilience and support from healthcare professionals associated with QoL...
5.
Hermansen J, Wojcik D, Robinson N, Pahnke J, Haugland H, Jamtoy A, et al.
Cancer Rep (Hoboken)
. 2021 Sep;
5(8):e1555.
PMID: 34541832
Background: The rapidly expanding era of "omics" research is highly dependent on the availability of quality-proven biological material, especially for rare conditions such as pediatric malignancies. Professional biobanks provide such...
6.
Toksvang L, Grell K, Nersting J, Degn M, Nielsen S, Abrahamsson J, et al.
Leukemia
. 2021 Jun;
36(1):33-41.
PMID: 34175901
Methotrexate/6-mercaptopurine maintenance therapy improves acute lymphoblastic leukemia (ALL) outcome. Cytotoxicity is mediated by DNA incorporation of thioguanine nucleotides (DNA-TG). We investigated the association of DNA-TG to relapse risk in 1 ...
7.
Nygaard Nielsen S, Toksvang L, Grell K, Nersting J, Abrahamsson J, Lund B, et al.
Cancer Chemother Pharmacol
. 2021 Apr;
88(2):271-279.
PMID: 33928426
Purpose: 6-mercaptopurine(6MP)/methotrexate maintenance therapy is essential to reduce relapse of childhood acute lymphoblastic leukemia (ALL). Common germline variants in TPMT cause low activity of thiopurine methyltransferase (TPMT) and higher 6MP...
8.
Dreisig K, Brunner E, Marquart H, Helt L, Nersting J, Frandsen T, et al.
Pediatr Hematol Oncol
. 2020 Nov;
38(3):227-238.
PMID: 33205673
Bone marrow minimal residual disease (MRD) is the strongest predictor of relapse in children with acute lymphoblastic leukemia (ALL). 6-mercaptopurine (6MP) in ALL therapy has wide inter-individual variation in disposition...
9.
Hojfeldt S, Grell K, Abrahamsson J, Lund B, Vettenranta K, Jonsson O, et al.
Blood
. 2020 Nov;
137(17):2373-2382.
PMID: 33150360
Truncation of asparaginase treatment due to asparaginase-related toxicities or silent inactivation (SI) is common and may increase relapse risk in acute lymphoblastic leukemia (ALL). We investigated relapse risk following suboptimal...
10.
Wolska-Kusnierz B, Pastorczak A, Fendler W, Wakulinska A, Dembowska-Baginska B, Heropolitanska-Pliszka E, et al.
Clin Cancer Res
. 2020 Oct;
27(2):575-584.
PMID: 33082212
Purpose: Nijmegen breakage syndrome (NBS) is a DNA repair disorder with a high predisposition to hematologic malignancies. Experimental Design: We describe the natural history of NBS, including cancer incidence, risk...